Results 1 to 10 of about 169,335 (161)
American Journal of Respiratory and Critical Care Medicine, 2022 Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of ...
Toby Maher +2 more
exaly +2 more sources
Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis
Scientific Reports, 2023 Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while unknown disease etiology.
Zenan Wu +7 more
doaj +2 more sources
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
New England Journal of Medicine, 2014 BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations
Ganesh Raghu +2 more
exaly +2 more sources
Macrophage polarization and its impact on idiopathic pulmonary fibrosis
Frontiers in ImmunologyIdiopathic pulmonary fibrosis (IPF) is a lung disease that worsens over time, causing fibrosis in the lungs and ultimately resulting in respiratory failure and a high risk of death.
Zhouling Ge +4 more
exaly +2 more sources
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
Frontiers in Immunology, 2021 The immune system is receiving increasing attention for interstitial lung diseases, as knowledge on its role in fibrosis development and response to therapies is expanding. Uncontrolled immune responses and unbalanced injury-inflammation-repair processes
Chiel van Geffen +10 more
doaj +2 more sources
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
New England Journal of Medicine, 2014 David Lederer +2 more
exaly +2 more sources
Idiopathic pulmonary fibrosis: current diagnosis and treatment [PDF]
Jornal Brasileiro de Pneumologia, 2023 Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients’ care in the past decade ...
Alexandre Franco Amaral +2 more
doaj +1 more source
Global incidence and prevalence of idiopathic pulmonary fibrosis
Respiratory Research, 2021 Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear.
T. Maher +7 more
semanticscholar +1 more source
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.
PLoS ONE, 2021 Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi +11 more
doaj +1 more source
Pulmonary Circulation, 2021 The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan +7 more
doaj +1 more source